Last Updated : September 23, 2014
Details
FilesGeneric Name:
Aflibercept
Project Status:
Complete
Therapeutic Area:
Metastatic Colorectal Cancer
Manufacturer:
Sanofi-aventis Canada Inc.
Brand Name:
Zaltrap
Project Line:
Reimbursement Review
Project Number:
PC0035-000
Performance Metric:
N/A — Predated performance metrics
Strength:
25mg/mL
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
In combination with irinotecan-fluoropyrimidine (FOLFIRI) based therapy for patients with metastatic colorectal cancer previously treated with an oxaliplatin-containing regimen
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Sanofi-aventis Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Recommendation Type:
Do not reimburse
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : September 23, 2014